GLORIA

GEOMAR Library Ocean Research Information Access

X

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • Cambria, V.  (2)
  • 2020-2024  (2)
Material
Publisher
Person/Organisation
Language
Years
  • 2020-2024  (2)
Year
  • 1
    Online Resource
    Online Resource
    First but not second postoperative day growth hormone assessments as early predictive tests for long-term acromegaly persistence
    Springer Science and Business Media LLC ; 2021
    In:  Journal of Endocrinological Investigation Vol. 44, No. 11 ( 2021-11), p. 2427-2433
    Details
    In: Journal of Endocrinological Investigation, Springer Science and Business Media LLC, Vol. 44, No. 11 ( 2021-11), p. 2427-2433
    Abstract: Postoperative assessment of acromegaly activity is typically performed at least 3 months after neurosurgery (NS). Few studies have evaluated the use of early postoperative growth hormone (GH) levels as a test to predict short- and long-term remission of acromegaly. Our objective was to evaluate the diagnostic performance of serum random GH on a postoperative day one (D1-rGH) and two (D2-rGH), particularly in predicting long-term disease persistence. Materials and methods Forty-one subjects with acromegaly who were undergoing NS were enrolled (mean age ± SD 47.4 ± 13.1 years at diagnosis; women 54%; macroadenomas 71%). The final assessment of disease activity was performed one year after NS. ROC curves were used to evaluate the diagnostic performance of D1-rGH and D2-rGH. Results After a 1-year follow-up, the overall remission rate was 55%. ROC analysis identified an optimal D1-rGH cut-off value of 2.1 ng/mL for diagnosing long-term disease persistence (55.6% SE; 90.9% SP). The cut-off point became 2.5 ng/mL after maximizing specificity for disease persistence (yielding a 100% positive predictive value) and 0.3 ng/mL after maximizing sensitivity for disease remission. The optimal D2-rGH cut-off value was 0.6 ng/mL (81.8% SE; 50% SP); the cut-off point became 2.9 ng/mL after maximizing specificity and 0.1 ng/mL after maximizing sensitivity, with no clinical utility. Conclusions D1-rGH could be a highly specific test for the early diagnosis of long-term acromegaly persistence, which is predicted by a value  〉  2.5 ng/mL with a great degree of certainty. The diagnostic performance of D2-rGH was insufficient. Further research is required to validate these preliminary results prior to modifying the postoperative management of acromegaly.
    Type of Medium: Online Resource
    ISSN: 1720-8386
    URL: Article
    DOI: 10.1007/s40618-021-01553-0
    Language: English
    Publisher: Springer Science and Business Media LLC
    Publication Date: 2021
    detail.hit.zdb_id: 2119482-8
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 2
    Online Resource
    Online Resource
    Increased prevalence of impulse control disorder symptoms in endocrine diseases treated with dopamine agonists: a cross-sectional study
    Springer Science and Business Media LLC ; 2021
    In:  Journal of Endocrinological Investigation Vol. 44, No. 8 ( 2021-08), p. 1699-1706
    Details
    In: Journal of Endocrinological Investigation, Springer Science and Business Media LLC, Vol. 44, No. 8 ( 2021-08), p. 1699-1706
    Abstract: Impulse control disorders (ICDs) have been described as a side effect of dopamine agonists (DAs) in neurological as well as endocrine conditions. Few studies have evaluated the neuropsychological effect of DAs in hyperprolactinemic patients, and these have reported a relationship between DAs and ICDs. Our objective was to screen for ICD symptoms in individuals with DA-treated endocrine conditions. Materials and methods A cross-sectional analysis was conducted on 132 patients with pituitary disorders treated with DAs (DA exposed), as well as 58 patients with pituitary disorders and no history of DA exposure (non-DA exposed). Participants responded to the full version of the Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s disease (QUIP). Results Compared with the non-DA-exposed group, a higher prevalence of DA-exposed patients tested positive for symptoms of any ICD or related behavior (52% vs. 31%, p   〈  0.01), any ICD (46% vs. 24%, p   〈  0.01), any related behavior (31% vs. 17%, p   〈  0.05), compulsive sexual behavior (27% vs. 14%, p   〈  0.04), and punding (20% vs. 7%, p   〈  0.02) by QUIP. On univariate analysis, DA treatment was associated with a two- to threefold increased risk of any ICD or related behavior [odds ratio (OR) 2.43] and any ICD (OR 2.70). In a multivariate analysis, independent risk factors for any ICD or related behavior were DA use (adjusted OR 2.22) and age (adjusted OR 6.76). Male gender was predictive of the risk of hypersexuality (adjusted OR 3.82). Discussion Despite the QUIP limitations, a clear sign of increased risk of ICDs emerges in individuals with DA-treated pituitary disorders. Our data contribute to the growing evidence of DA-induced ICDs in endocrine conditions.
    Type of Medium: Online Resource
    ISSN: 1720-8386
    URL: Article
    DOI: 10.1007/s40618-020-01478-0
    Language: English
    Publisher: Springer Science and Business Media LLC
    Publication Date: 2021
    detail.hit.zdb_id: 2119482-8
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...